Taken together, our study uncovers key baseline determinants of response to adalimumab in psoriasis at molecular and cellular levels, from the more proximal signalling events, such as NF-κB activation in cDC2, to the ultimate effect on pathogenic IL-17+ T cells in blood and skin. The gene discussed is NFKB1; the disease is psoriasis.